Skip to content

Study · Case report or series · n = 1 · 2008

10 results

Treatment of adult hypophosphatasia with teriparatide.

Camacho PM, Painter S, Kadanoff R

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists1 Mar 2008Cited by 32 (Europe PMC)

PMID18308659 (opens in a new tab)DOI10.4158/ep.14.2.204 (opens in a new tab)PepBankPUB-18308659
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a woman with hypophosphatasia, BSALP reached the lower reference limit at 16 U/L after about 1.5 years of teriparatide.

    In plain wordsA woman's bone alkaline phosphatase reached the lower normal limit during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBSALP at about 1.5 years
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg daily · subcutaneous · 24 monthsAs given in this study (human).

    Measurements

    BSALP at about 1.5 years
    16 U/L
    single patient on teriparatide

    Source sentences

    Summary
    After about 1.5 years of teriparatide therapy, BSALP reached the lower end of the reference range at 16 U/L, and after 24 months of continuous teriparatide treatment, both serum total alkaline phosphatase and BSALP normalized at 30 U/L and 18 U/L, respectively.
    2 context sentences
    Summary · context
    To describe the effects of 24 months of teriparatide therapy in an adult with hypophosphatasia, which thus far has no established medical treatment.
    Summary · context
    Teriparatide, synthetic parathyroid hormone(1-34), in a dosage of 20 microg subcutaneously was given daily from April 2004 until June 2006.
  2. 02HumanCase report or seriesEfficacy outcome

    In a woman with hypophosphatasia, total alkaline phosphatase normalized at 30 U/L after 24 months of teriparatide.

    In plain wordsA woman's total alkaline phosphatase increased to normal during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTotal alkaline phosphatase at 24 months
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg daily · subcutaneous · 24 monthsAs given in this study (human).

    Measurements

    Serum total alkaline phosphatase at 24 months
    30 U/L
    single patient on teriparatide

    Source sentences

    Summary
    After about 1.5 years of teriparatide therapy, BSALP reached the lower end of the reference range at 16 U/L, and after 24 months of continuous teriparatide treatment, both serum total alkaline phosphatase and BSALP normalized at 30 U/L and 18 U/L, respectively.
    2 context sentences
    Summary · context
    To describe the effects of 24 months of teriparatide therapy in an adult with hypophosphatasia, which thus far has no established medical treatment.
    Summary · context
    Teriparatide, synthetic parathyroid hormone(1-34), in a dosage of 20 microg subcutaneously was given daily from April 2004 until June 2006.
  3. 03HumanCase report or seriesEfficacy outcome

    In a woman with hypophosphatasia, BSALP normalized at 18 U/L after 24 months of teriparatide.

    In plain wordsA woman's bone alkaline phosphatase increased to normal during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBSALP at 24 months
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg daily · subcutaneous · 24 monthsAs given in this study (human).

    Measurements

    BSALP at 24 months
    18 U/L
    single patient on teriparatide

    Source sentences

    Summary
    After about 1.5 years of teriparatide therapy, BSALP reached the lower end of the reference range at 16 U/L, and after 24 months of continuous teriparatide treatment, both serum total alkaline phosphatase and BSALP normalized at 30 U/L and 18 U/L, respectively.
    2 context sentences
    Summary · context
    To describe the effects of 24 months of teriparatide therapy in an adult with hypophosphatasia, which thus far has no established medical treatment.
    Summary · context
    Teriparatide, synthetic parathyroid hormone(1-34), in a dosage of 20 microg subcutaneously was given daily from April 2004 until June 2006.
  4. 04HumanCase report or seriesEfficacy outcome

    In a woman with hypophosphatasia, pyridoxal 5'-phosphate declined from 250 to 188 ng/mL after 17 months of teriparatide.

    In plain wordsA woman's pyridoxal phosphate decreased compared with baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreasePyridoxal 5'-phosphate
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg daily · subcutaneous · 24 monthsAs given in this study (human).

    Measurements

    Pyridoxal 5'-phosphate at baseline
    250 ng/mL
    single patient, baseline
    Pyridoxal 5'-phosphate after 17 months
    188 ng/mL
    single patient on teriparatide

    Source sentences

    Summary
    Pyridoxal 5'-phosphate declined from a baseline of 250 to 188 ng/mL after 17 months of treatment.
    2 context sentences
    Summary · context
    To describe the effects of 24 months of teriparatide therapy in an adult with hypophosphatasia, which thus far has no established medical treatment.
    Summary · context
    Teriparatide, synthetic parathyroid hormone(1-34), in a dosage of 20 microg subcutaneously was given daily from April 2004 until June 2006.
  5. 05HumanCase report or seriesEfficacy outcome

    In a woman with hypophosphatasia, urinary N-telopeptide increased from <6 to 19 after 17 months of teriparatide.

    In plain wordsA woman's urinary N-telopeptide increased compared with baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseUrinary N-telopeptide at 17 months
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg daily · subcutaneous · 24 monthsAs given in this study (human).

    Measurements

    Urinary N-telopeptide at baseline
    < 6 bone collagen equivalents/mmol creatinine
    single patient, baseline
    Urinary N-telopeptide after 17 months
    19 bone collagen equivalents/mmol creatinine
    single patient on teriparatide

    Source sentences

    Summary
    Urinary N-telopeptide increased from a baseline of <6 to 19 after 17 months and to 70 bone collagen equivalents/mmol creatinine after 24 months of anabolic therapy.
    2 context sentences
    Summary · context
    To describe the effects of 24 months of teriparatide therapy in an adult with hypophosphatasia, which thus far has no established medical treatment.
    Summary · context
    Teriparatide, synthetic parathyroid hormone(1-34), in a dosage of 20 microg subcutaneously was given daily from April 2004 until June 2006.
  6. 06HumanCase report or seriesEfficacy outcome

    In a woman with hypophosphatasia, urinary N-telopeptide reached 70 bone collagen equivalents/mmol creatinine after 24 months of teriparatide.

    In plain wordsA woman's urinary N-telopeptide increased further during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseUrinary N-telopeptide at 24 months
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg daily · subcutaneous · 24 monthsAs given in this study (human).

    Measurements

    Urinary N-telopeptide at baseline
    < 6 bone collagen equivalents/mmol creatinine
    single patient, baseline
    Urinary N-telopeptide after 24 months
    70 bone collagen equivalents/mmol creatinine
    single patient on teriparatide

    Source sentences

    Summary
    Urinary N-telopeptide increased from a baseline of <6 to 19 after 17 months and to 70 bone collagen equivalents/mmol creatinine after 24 months of anabolic therapy.
    2 context sentences
    Summary · context
    To describe the effects of 24 months of teriparatide therapy in an adult with hypophosphatasia, which thus far has no established medical treatment.
    Summary · context
    Teriparatide, synthetic parathyroid hormone(1-34), in a dosage of 20 microg subcutaneously was given daily from April 2004 until June 2006.
  7. 07HumanCase report or seriesEfficacy outcome

    In a woman with hypophosphatasia, lumbar spine BMD improved substantially during teriparatide treatment compared with baseline.

    In plain wordsA woman's spine bone density improved compared with baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg daily · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Repeated DXA scanning showed a substantial improvement in lumbar spine BMD and stability in hip BMD.
    2 context sentences
    Summary · context
    To describe the effects of 24 months of teriparatide therapy in an adult with hypophosphatasia, which thus far has no established medical treatment.
    Summary · context
    Teriparatide, synthetic parathyroid hormone(1-34), in a dosage of 20 microg subcutaneously was given daily from April 2004 until June 2006.
  8. 08HumanCase report or seriesEfficacy outcome

    In a woman with hypophosphatasia, hip BMD remained stable during teriparatide treatment.

    In plain wordsA woman's hip bone density remained stable during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeHip BMD
    Study

    n = 1

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg daily · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Repeated DXA scanning showed a substantial improvement in lumbar spine BMD and stability in hip BMD.
    2 context sentences
    Summary · context
    To describe the effects of 24 months of teriparatide therapy in an adult with hypophosphatasia, which thus far has no established medical treatment.
    Summary · context
    Teriparatide, synthetic parathyroid hormone(1-34), in a dosage of 20 microg subcutaneously was given daily from April 2004 until June 2006.
  9. 09HumanCase report or seriesEfficacy outcome

    A woman with hypophosphatasia experienced no clinical fractures during teriparatide treatment.

    In plain wordsA woman with hypophosphatasia had no clinical fractures during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableClinical fractures
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg daily · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    The patient experienced no clinical fractures or adverse events during teriparatide therapy.
    2 context sentences
    Summary · context
    To describe the effects of 24 months of teriparatide therapy in an adult with hypophosphatasia, which thus far has no established medical treatment.
    Summary · context
    Teriparatide, synthetic parathyroid hormone(1-34), in a dosage of 20 microg subcutaneously was given daily from April 2004 until June 2006.
  10. 10HumanCase report or seriesSafety outcome

    A woman with hypophosphatasia experienced no adverse events during teriparatide treatment.

    In plain wordsA woman with hypophosphatasia had no adverse events during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableAdverse events
    Study

    n = 1

    Outcome group
    Adverse events · Whole body
    Studied dose
    20 microg daily · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    The patient experienced no clinical fractures or adverse events during teriparatide therapy.
    2 context sentences
    Summary · context
    To describe the effects of 24 months of teriparatide therapy in an adult with hypophosphatasia, which thus far has no established medical treatment.
    Summary · context
    Teriparatide, synthetic parathyroid hormone(1-34), in a dosage of 20 microg subcutaneously was given daily from April 2004 until June 2006.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.